Patents by Inventor Mustafa Guzel

Mustafa Guzel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
    Publication number: 20230312548
    Abstract: Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating renal diseases are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.
    Type: Application
    Filed: April 3, 2023
    Publication date: October 5, 2023
    Inventors: Adnan M.M. MJALLI, Dharma Rao POLISETTI, Jareer Nabeel KASSIS, Matthew J. KOSTURA, Mustafa GUZEL, Otis Clinton ATTUCKS, Robert Carl ANDREWS, Samuel VICTORY, Suparna GUPTA
  • Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
    Patent number: 11649230
    Abstract: Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating renal diseases are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.
    Type: Grant
    Filed: August 11, 2021
    Date of Patent: May 16, 2023
    Assignee: VTV THERAPEUTICS LLC
    Inventors: Adnan M. M. Mjalli, Dharma Rao Polisetti, Jareer Nabeel Kassis, Matthew J. Kostura, Mustafa Guzel, Otis Clinton Attucks, Robert Carl Andrews, Samuel Victory, Suparna Gupta
  • Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof
    Publication number: 20220169641
    Abstract: Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating renal diseases are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.
    Type: Application
    Filed: August 11, 2021
    Publication date: June 2, 2022
    Inventors: Adnan M.M. Mjalli, Dharma Rao Polisetti, Jareer Nabeel Kassis, Matthew J. Kostura, Mustafa Guzel, Otis Clinton Attucks, Robert Carl Andrews, Samuel Victory, Suparna Gupta
  • NAPHTHALIMIDE DERIVATIVES AS ANTI-PARASITIC AGENTS FOR THE TREATMENT OF LEISHMANIASIS AS WELL AS VIRAL, BACTERIAL AND NEOPLASTIC DISEASES
    Publication number: 20220143005
    Abstract: Disclosed are naphthalimide derivatives and in particular e.g. N-aryl-substituted naphthalimidopropylamine derivatives (i.e. 2-[3-(amino)propyl]-1H-benz[de]isoquinoline-1,3(2H)-dione derivatives) such as e.g. such as e.g. (Formula I) or (Formula III) as anti-parasitic agents for the treatment of Leishmaniasis. The compounds could also be useful to treat viral, bacterial and/or neoplastic diseases. The description discloses exemplary synthesis as well as biological tests against Leishmania infantum parasites (e.g. pages 54 to 58; examples 1 to 7). Exemplary compounds are: (example 3)(example 4) 2-(3-((5-amino naphthalene-1-yl)amino)propyl)-1H-benzo[de]isoquinoline-1, 3(2H)-dione (example 5) 2-(3-((5-amino naphthalene-1-yl)amino)propyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (example 6).
    Type: Application
    Filed: December 24, 2019
    Publication date: May 12, 2022
    Inventors: Mustafa GUZEL, Mehmet Hikmet ÜÇISIK, Fikrettin SAHIN, Elif KESKIN, Zeynep ISLEK
  • Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
    Patent number: 11130753
    Abstract: Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating renal diseases are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: September 28, 2021
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Dharma Rao Polisetti, Jareer Nabeel Kassis, Matthew J. Kostura, Mustafa Guzel, Otis Clinton Attucks, Robert Carl Andrews, Samuel Victory, Suparna Gupta
  • Heterobivalent ligands suitable for use in the treatment of Parkinson's disease
    Patent number: 11053270
    Abstract: Disclosed are novel drug molecules and use of the novel drug molecules in the treatment of neurodegenerative diseases, such as Parkinson's disease.
    Type: Grant
    Filed: April 14, 2018
    Date of Patent: July 6, 2021
    Inventors: Özge Sensoy, Mustafa Güzel, Bilal Ersen Kerman, Neslihan Üstündag Okur, Samman Mansoor, Essam Hanashalshahaby, Elif Keskin, Serdar Durdagi, Gülru Kayik
  • HETEROBIVALENT LIGANDS SUITABLE FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE
    Publication number: 20210147421
    Abstract: Disclosed are novel drug molecules and use of the novel drug molecules in the treatment of neurodegenerative diseases, such as Parkinson's disease.
    Type: Application
    Filed: April 14, 2018
    Publication date: May 20, 2021
    Inventors: Özge SENSOY, Mustafa GÜZEL, Bilal Ersen KERMAN, Neslihan ÜSTÜNDAG OKUR, Samman MANSOOR, Essam HANASHALSHAHABY, Elif KESKIN, Serdar DURDAGI, Gülru KAYIK
  • Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
    Patent number: 10889580
    Abstract: Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating non-alcoholic steatohepatitis are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: January 12, 2021
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Dharma Rao Polisetti, Jareer Nabeel Kassis, Matthew J. Kostura, Mustafa Guzel, Otis Clinton Attucks, Robert Carl Andrews, Samuel Victory, Suparna Gupta
  • Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof
    Publication number: 20210002268
    Abstract: Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating renal diseases are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.
    Type: Application
    Filed: September 22, 2020
    Publication date: January 7, 2021
    Inventors: Adnan M.M. Mjalli, Dharma Rao Polisetti, Jareer Nabeel Kassis, Matthew J. Kostura, Mustafa Guzel, Otis Clinton Attucks, Robert Carl Andrews, Samuel Victory, Suparna Gupta
  • Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof
    Publication number: 20200148673
    Abstract: Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating non-alcoholic steatohepatitis are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.
    Type: Application
    Filed: January 10, 2020
    Publication date: May 14, 2020
    Inventors: Adnan M.M. Mjalli, Dharma Rao Polisetti, Jareer Nabeel Kassis, Matthew J. Kostura, Mustafa Guzel, Otis Clinton Attucks, Robert Carl Andrews, Samuel Victory, Suparna Gupta
  • Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors
    Patent number: 10568888
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4 including, but not limited to, allergic rhinitis.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: February 25, 2020
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
  • Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
    Patent number: 10570126
    Abstract: Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating conditions or diseases of the eye are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: February 25, 2020
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Dharma Rao Polisetti, Jareer Nabeel Kassis, Matthew J. Kostura, Mustafa Guzel, Otis Clinton Attucks, Robert Carl Andrews, Samuel Victory, Suparna Gupta
  • TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS
    Publication number: 20190336506
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4 including, but not limited to, allergic rhinitis.
    Type: Application
    Filed: July 10, 2019
    Publication date: November 7, 2019
    Inventors: Adnan M. M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
  • Compositions and Methods for Inhibiting Metastasis
    Publication number: 20190298746
    Abstract: Calprotectin inhibitors and derivatives thereof, and methods of using them for inhibiting or reducing metastatis and treating cancer are provided. The pharmaceutical formulations prepared from the compounds can be used in the treatment of cancer either as a single agent or in combination with at least one other cancer therapeutic, chemotherapeutic or anti-cancer agent.
    Type: Application
    Filed: March 27, 2019
    Publication date: October 3, 2019
    Inventors: Hasan Korkaya, Eunmi Lee, Mustafa Guzel
  • Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors
    Patent number: 10391097
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4, including but not limited to ulcerative colitis and Crohn's disease.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: August 27, 2019
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
  • Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof
    Publication number: 20190194181
    Abstract: Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating conditions or diseases of the eye are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.
    Type: Application
    Filed: March 5, 2019
    Publication date: June 27, 2019
    Inventors: Adnan M.M. Mjalli, Dharma Rao Polisetti, Jareer Nabeel Kassis, Matthew J. Kostura, Mustafa Guzel, Otis Clinton Attucks, Robert Carl Andrews, Samuel Victory, Suparna Gupta
  • Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
    Patent number: 10287284
    Abstract: Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating inflammation are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: May 14, 2019
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Dharma Rao Polisetti, Jareer Nabeel Kassis, Matthew J. Kostura, Mustafa Guzel, Otis Clinton Attucks, Robert Carl Andrews, Samuel Victory, Suparna Gupta
  • TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS
    Publication number: 20180360839
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4, including but not limited to ulcerative colitis and Crohn's disease.
    Type: Application
    Filed: August 27, 2018
    Publication date: December 20, 2018
    Inventors: Adnan M. M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel
  • Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof
    Publication number: 20180291015
    Abstract: Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating inflammation are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.
    Type: Application
    Filed: June 13, 2018
    Publication date: October 11, 2018
    Inventors: Adnan M.M. Mjalli, Dharma Rao Polisetti, Jareer Nabeel Kassis, Matthew J. Kostura, Mustafa Guzel, Otis Clinton Attucks, Robert Carl Andrews, Samuel Victory, Suparna Gupta
  • Tricyclic compounds as modulators of TNF-? synthesis and as PDE4 inhibitors
    Patent number: 10085990
    Abstract: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-? or by PDE4, including but not limited to ulcerative colitis and Crohn's disease.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: October 2, 2018
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Bapu Gaddam, Dharma Rao Polisetti, Matthew J. Kostura, Mustafa Guzel